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Immediate and long-term consequences of
COVID-19 infections for the development
of neurological disease
Michael T. Heneka1,2,3* , Douglas Golenbock2, Eicke Latz2,3,4, Dave Morgan5 and Robert Brown6
Abstract
Increasing evidence suggests that infection with Sars-CoV-2 causes neurological deficits in a substantial proportion of
affected patients. While these symptoms arise acutely during the course of infection, less is known about the possible long-
term consequences for the brain. Severely affected COVID-19 cases experience high levels of proinflammatory cytokines and
acute respiratory dysfunction and often require assisted ventilation. All these factors have been suggested to cause cognitive
decline. Pathogenetically, this may result from direct negative effects of the immune reaction, acceleration or aggravation of
pre-existing cognitive deficits, or de novo induction of a neurodegenerative disease. This article summarizes the current
understanding of neurological symptoms of COVID-19 and hypothesizes that affected patients may be at higher risk of
developing cognitive decline after overcoming the primary COVID-19 infection. A structured prospective evaluation should
analyze the likelihood, time course, and severity of cognitive impairment following the COVID-19 pandemic.
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Background
The COVID-19 pandemic represents an unprecedented
immediate but also persisting threat to our health care
systems. The immediate urgency is clear, as the total
number of affected patients exceeds most of the health
care system capacities worldwide, particularly for the
treatment of patients requiring assisted ventilation. Less
immediately apparent, but potentially very significant are
long-term consequences of COVID-19 infections.
During the acute phase of COVID-19 infection, about
36% of cases develop neurological symptoms of which
25% can be attributed to the direct involvement of the
central nervous system. The main symptoms include but
are not restricted to dizziness, headache, impaired
consciousness, and seizure [1]. Patients who show
neurological symptoms included cases with or without
pre-existing neurological disorders [2]. While on inten-
sive care units, patients showed agitation, confusion, and
corticospinal tract signs such as enhanced tendon re-
flexes and clonus. In mild to moderate disease cases, pa-
tients reported olfactory (85.6%) and gustatory (88.0%)
dysfunctions. Importantly, in about 11% of patients, an-
osmia occurred prior to any other clinical symptoms [3].
COVID-19 can further lead to changes of coagulation
and, in particular, to inflammation-induced disseminated
intravascular coagulation (DIC). Together with endothe-
lial dysfunction, DIC can cause cerebrovascular ischemia
even in young patients, many of whom suffer from large
vessel ischemic stroke [4, 5]. Overall, this may also be in-
fluenced by the severity of the COVID-19 infection, as
5.7% of the severe cases suffered from ischemic stroke
[1] or had pre-existing vascular risk factors, especially in
the elderly, in whom ischemic stroke rather occurred as
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a delayed complication [6, 7]. Additionally, as sub-acute
signs that occurred 3–10 days after the development of
Covid-19 symptoms, Guillain-Barré syndrome [8] and
Miller-Fisher syndrome [9] cases have been reported.
Also, clinically striking are cases of Kawaski-like multi-
system inflammatory syndromes now being recognized
in children and teenagers.
Main text
There are at least four possible pathogenic mechanisms
that may account for the detrimental effect of COVID-
19 on the CNS: (1) direct viral encephalitis, (2) systemic
inflammation, (3) peripheral organ dysfunction (liver,
kidney, lung), and (4) cerebrovascular changes. In most
cases, however, neurological manifestations of COVID-
19 may arise from a combination of the above.
Any one or a combination of these mechanisms put
COVID-19 survivors at risk for developing long-term
neurological consequences, either by aggravating a pre-
existing neurological disorder or by initiating a new dis-
order. This concern is supported by findings that show
that one third of patients at the time of discharge have
evidence of cognitive impairment and motor deficits [2].
This is particularly relevant because overall COVID-19
clinically affects the elderly most severely [10]. There is
a large overlap of the age range when people typically
develop neurodegenerative or cerebrovascular disease
and the age of risk for the most several COVID-19 infec-
tions. This overlap argues that there is a compelling
need for prospective neurological surveillance and care.
COVID-19 is associated with a severe innate immune
response and sustained rise of systemic cytokine levels.
Importantly, this innate immune response has been sug-
gested to drive and predict mortality and severity [11]. Cy-
tokines and related inflammatory mediators found to be
elevated include interleukin-1β, interleukin-2, interleukin-
2 receptor, interleukin-4, interleukin-10, interleukin-18,
interferon-γ, C-reactive protein, granulocyte colony-
stimulating factor, interferon-γ, CXCL10, monocyte
chemoattractant protein 1, macrophage inflammatory
protein 1-α, and tumor necrosis factor-α [10, 12]. Con-
comitantly, most patients show signs of T cell exhaustion
with lower lymphocyte counts. The fact that systemic in-
flammation has been shown to promote cognitive decline
and neurodegenerative disease makes it likely that
COVID-19 survivors will experience neurodegeneration in
the following years [13, 14]. Of note, cytokine levels can
predict the subsequent occurrence of hippocampal atro-
phy in patients that experience severe sepsis [15]. In keep-
ing with this, the most frequent clinical presentation of
COVID-19 is the development of acute respiratory dis-
tress syndrome (ARDS) [16], the latter being, along with
chronic ventilation, highly associated with subsequent
cognitive decline, executive dysfunction, and reduced
quality of life, often persisting months and years after hos-
pital discharge [17] reviewed in [18]. The causative role of
systemic inflammatory damage to the brain is further sup-
ported by the fact that none of the cerebrospinal fluid
samples investigated in the study by Helms et al. found
evidence for a direct presence of SARS-CoV-2 in the cere-
brospinal fluid [2]. That being said, one should not ig-
nore the potential importance of the single case
report of direct viral infiltration of the brain and viral
encephalitis, either by hematogenous or neuronal
retrograde dissemination [19].
Evidence from murine lung injury models and ARDS
patient samples emphasize the role of the NLRP3 inflam-
masome in the pathogenesis and detrimental outcome of
ARDS [20, 21]. In keeping with this, the coronavirus
ORF3a protein has been shown to induce NLRP3 inflam-
masome activity [22]. Moreover, ventilation-induced
hypercapnia has been experimentally shown to lead to
cognitive impairment in a NLRP3 inflammasome-
interleukin-1β-dependent manner [23]. Given the above
cytokine findings in COVID-19 patients and in particular
the rise of interleukin-1β and interleukin-18, it seems
highly likely that COVID-19 patients suffer from NLRP3
inflammasome activation. This activation and the subse-
quent increased activity of proinflammatory immune
pathways are likely to exert a negative impact on cerebral
homeostasis and function.
This conclusion is based on not only epidemiological
evidence but also on experiments that showed that sys-
temic, NLRP3 inflammasome-mediated inflammation
adversely affects beneficial immune functions in the
brain and thereby causes the pathological accumulation
of neurodegeneration-associated peptides such as fibril-
lar amyloid-β [24]. Thus, both peripheral and central in-
duction of the NLRP3 inflammasome can directly
induce or aggravate neurodegenerative processes that
lead to functional impairment in AD [25] or strongly
contribute to the spreading of pathology and thus the
progression of the disease [26]. The recent finding show-
ing that NLRP3-driven and interleukin-1β-mediated
modulation of phosphokinases and phosphatases largely
accounts for the pathological formation of neurofibrillary
tangles in murine models of tauopathy raises the con-
cern that COVID-19 patients are likely to experience an
induction or strong aggravation of neurodegenerative
processes [27].
Conclusion
Evidence strongly suggests that patients surviving
COVID-19 are at high risk for subsequent development
of neurological disease and in particular Alzheimer’s dis-
ease. Neurologists, psychiatrists, and caregivers should
be alerted to a possible increase in such cases in
COVID-19 survivors. Prospective studies are needed to
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investigate potential correlations between acute and sub-
acute COVID-19 infections and long-term neurological
sequalae in this patient cohort.
Abbreviations
AD: Alzheimer’s disease; ARDS: Acute respiratory distress syndrome; COVID-
19: Coronavirus SARS-CoV-2; CSF: Cerebrospinal fluid; NLRP3: NOD-, LRR-, and
pyrin domain-containing protein 3; ORF3a: Not characterized yet (UNIPROT)
Acknowledgements
This work was supported by the NIH grant (R01 AG059752-02) to DG and
MTH.
Authors’ contributions
All authors contributed equally to this viewpoint article. All authors read and
approved the final manuscript.
Funding
Not applicable.
Availability of data and materials
Not applicable.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Author details
1Department of Neurodegenerative Disease and Geriatric Psychiatry,
University of Bonn, Bonn, Germany. 2German Center for Neurodegenerative
Disease, Bonn, Germany. 3Division of Infectious Diseases and Immunology,
University of Massachusetts Medical School, Worcester, MA 01605, USA.
4Institute for Innate Immunity, University of Bonn, Bonn, Germany.
5Translational Neuroscience, College of Human Medicine, Michigan State
University, Grand Rapids, USA. 6Department of Neurology, University of
Massachusetts Medical School, Worcester, MA 01605, USA.
Received: 6 May 2020 Accepted: 27 May 2020
References
1. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations
of hospitalized patients with coronavirus disease 2019 in Wuhan, China.
JAMA Neurol. 2020:e201127.
2. Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, et al.
Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020:
NEJMc2008597.
3. Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez
A, et al. Olfactory and gustatory dysfunctions as a clinical presentation of
mild-to-moderate forms of the coronavirus disease (COVID-19): a
multicenter European study. Eur Arch Otorhinolaryngol. 2020;6:1–11.
4. Gonzalez-Pinto T, Luna-Rodriguez A, Moreno-Estebanez A, Agirre-Beitia G,
Rodriguez-Antiguedad A, Ruiz-Lopez M. Emergency room neurology in
times of COVID-19: malignant ischemic stroke and SARS-COV2 infection. Eur
J Neurol. 2020:ene.14286.
5. Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, et al. Large-
vessel stroke as a presenting feature of Covid-19 in the young. N Engl J
Med. 2020;382(20):e60.
6. Beyrouti R, Adams ME, Benjamin L, Cohen H, Farmer SF, Goh YY, et al.
Characteristics of ischaemic stroke associated with COVID-19. J Neurol
Neurosurg Psychiatry. 2020:jnnp-2020-323586.
7. Viguier A, Delamarre L, Duplantier J, Olivot JM, Bonneville F. Acute ischemic
stroke complicating common carotid artery thrombosis during a severe
COVID-19 infection. J Neuroradiol. 2020:S0150-9861(20)30159-0.
8. Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, et al.
Guillain-Barre syndrome associated with SARS-CoV-2. N Engl J Med. 2020:
NEJMc2009191.
9. Gutierrez-Ortiz C, Mendez A, Rodrigo-Rey S, San Pedro-Murillo E, Bermejo-
Guerrero L, Gordo-Manas R, et al. Miller fisher syndrome and polyneuritis
cranialis in COVID-19. Neurology. 2020. https://doi.org/10.1212/WNL.
0000000000009619.
10. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and
immunological features of severe and moderate coronavirus disease 2019. J
Clin Invest. 2020;130:2620–9.
11. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of
patients infected with 2019 novel coronavirus in Wuhan, China. Lancet.
2020;395(10223):497–506.
12. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al.
COVID-19: consider cytokine storm syndromes and immunosuppression.
Lancet. 2020;395(10229):1033–4.
13. Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long-term cognitive impairment
and functional disability among survivors of severe sepsis. JAMA. 2010;
304(16):1787–94.
14. Widmann CN, Heneka MT. Long-term cerebral consequences of sepsis.
Lancet Neurol. 2014;13(6):630–6.
15. Lindlau A, Widmann CN, Putensen C, Jessen F, Semmler A, Heneka MT.
Predictors of hippocampal atrophy in critically ill patients. Eur J Neurol.
2015;22(2):410–5.
16. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutierrez-Ocampo E, Villamizar-
Pena R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and
imaging features of COVID-19: a systematic review and meta-analysis. Travel
Med Infect Dis. 2020;34:101623.
17. Girard TD, Thompson JL, Pandharipande PP, Brummel NE, Jackson JC, Patel
MB, et al. Clinical phenotypes of delirium during critical illness and severity
of subsequent long-term cognitive impairment: a prospective cohort study.
Lancet Respir Med. 2018;6(3):213–22.
18. Sasannejad C, Ely EW, Lahiri S. Long-term cognitive impairment after acute
respiratory distress syndrome: a review of clinical impact and
pathophysiological mechanisms. Crit Care. 2019;23(1):352.
19. Zhou L, Zhang M, Wang J, Gao J. Sars-Cov-2: underestimated damage to
nervous system. Travel Med Infect Dis. 2020;101642.
20. Jones HD, Crother TR, Gonzalez-Villalobos RA, Jupelli M, Chen S, Dagvadorj
J, et al. The NLRP3 inflammasome is required for the development of
hypoxemia in LPS/mechanical ventilation acute lung injury. Am J Respir Cell
Mol Biol. 2014;50(2):270–80.
21. Feng Z, Qi S, Zhang Y, Qi Z, Yan L, Zhou J, et al. Ly6G+ neutrophil-derived
miR-223 inhibits the NLRP3 inflammasome in mitochondrial DAMP-induced
acute lung injury. Cell Death Dis. 2017;8(11):e3170.
22. Siu KL, Yuen KS, Castano-Rodriguez C, Ye ZW, Yeung ML, Fung SY, et al.
Severe acute respiratory syndrome coronavirus ORF3a protein activates the
NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of
ASC. FASEB J. 2019;33(8):8865–77.
23. Ding HG, Deng YY, Yang RQ, Wang QS, Jiang WQ, Han YL, et al.
Hypercapnia induces IL-1beta overproduction via activation of NLRP3
inflammasome: implication in cognitive impairment in hypoxemic adult rats.
J Neuroinflammation. 2018;15(1):4.
24. Tejera D, Mercan D, Sanchez-Caro JM, Hanan M, Greenberg D, Soreq H,
et al. Systemic inflammation impairs microglial Aβ clearance through NLRP3
inflammasome. EMBO J. 2019;38(17):e101064.
25. Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A,
et al. NLRP3 is activated in Alzheimer’s disease and contributes to
pathology in APP/PS1 mice. Nature. 2013;493(7434):674–8.
26. Venegas C, Kumar S, Franklin BS, Dierkes T, Brinkschulte R, Tejera D, et al.
Microglia-derived ASC specks cross-seed amyloid-beta in Alzheimer’s
disease. Nature. 2017;552(7685):355–61.
27. Ising C, Venegas C, Zhang S, Scheiblich H, Schmidt SV, Vieira-Saecker A,
et al. NLRP3 inflammasome activation drives tau pathology. Nature. 2019;
575(7784):669–73.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Heneka et al. Alzheimer's Research & Therapy           (2020) 12:69 Page 3 of 3
